Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;62(3):366-369.
doi: 10.20945/2359-3997000000044. Epub 2018 May 17.

Graves' ophthalmopathy: low-dose dexamethasone reduces retinoic acid receptor-alpha gene expression in orbital fibroblasts

Affiliations

Graves' ophthalmopathy: low-dose dexamethasone reduces retinoic acid receptor-alpha gene expression in orbital fibroblasts

Sarah Santiloni Cury et al. Arch Endocrinol Metab. 2018 Jun.

Abstract

Objective: Graves' ophthalmopathy (GO) is an autoimmune disease that leads to ocular proptosis caused by fat accumulation and inflammation, and the main treatment is corticosteroid therapy. Retinoid acid receptor-alpha (RARα) seems to be associated with inflammation and adipocyte differentiation. This study aimed to assess the effect of glucocorticoid treatment on orbital fibroblasts of GO patient treated or not with different glucocorticoid doses.

Materials and methods: Orbital fibroblasts collected during orbital decompression of a female patient with moderately severe/severe GO were cultivated and treated with 10 nM and 100 nM dexamethasone (Dex). rRARα gene expression in the treated and untreated cells was then compared.

Results: Fibroblast RARα expression was not affected by 100 nM Dex. On the other hand, RARα expression was 24% lower in cells treated with 10 nM Dex (p < 0.05).

Conclusions: Orbital fibroblasts from a GO patient expressed the RARα gene, which was unaffected by higher, but decreased with lower doses of glucocorticoid.

PubMed Disclaimer

Conflict of interest statement

Disclosure: no potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1. Effect of 10 nM and 100 nM dexamethasone on retinoic acid receptor alpha (RARα) mRNA in orbital fibroblasts from a patient with Graves’ ophthalmopathy. The experiment was performed in triplicate. Data were reported as mean and standard deviation. ANOVA was used in conjunction with Tukey's test (p < 0.05).
ns: not significant.

References

    1. Iyer S, Bahn R. Immunopathogenesis of Graves’ ophthalmopathy: the role of the TSH receptor. Best Pract Res Clin Endocrinol Metab. 2012;26(3):281-9. - PMC - PubMed
    1. Bahn R. High-dose intravenous glucocorticoid therapy for Graves’ ophthalmopathy: where are we now? Thyroid. 2012;22(1):1-2. - PubMed
    1. Philip R, Saran S, Gutch M, Agroyia P, Tyagi R, Gupta K. Pulse dexamethasone therapy versus pulse methylprednisolone therapy for treatment of Graves's ophthalmopathy. Indian J Endocrinol Metab. 2013;17(Suppl 1):S157-9. - PMC - PubMed
    1. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al.; European Group on Graves’ Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;5(1):9-26. - PMC - PubMed
    1. Owen CE. Treating acne with high-dose isotretinoin. JAMA. 2014;311(20):2121-2. - PubMed

MeSH terms

LinkOut - more resources